Publications by authors named "Guihui Tu"

Claim this Profile
D
DNA damage agents trigger iNKT cell-mediated elimination of AML cells through activation of NF-κB/HLA-DRB6/CD1d pathway.
Guihui Tu, Qiurong Wu, Yuxia Yuan, Qingna Jiang, Yuanling Tang

Biochem Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SP1-SuperEnhancer-SPHK1 Axis Mediates Niraparib Resistance in TNBC.
Yu-Xia Yuan, Rui-Jia Chen, Gui-Hui Tu, Chao-Qi Li, Long-Long Xu

Pharmaceuticals (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Molecular Chaperone TCP1 Affects Carcinogenicity and Is a Potential Therapeutic Target for Acute Myeloid Leukemia.
Yong Wu, Guihui Tu, Yuxia Yuan, Jingwen Liu, Qingna Jiang

Pharmaceutics· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer.
Qingna Jiang, Minghai Fu, Yuanling Tang, Ge Li, Guihui Tu

Eur J Med Chem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 .
Qingna Jiang, Yan Hu, Quanyu Liu, Yuanling Tang, Xinhua Wu, Guihui Tu

J Drug Target· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
Ge Li, Shan-Shan Lin, Ze-Lei Yu, Xin-Hua Wu, Jing-Wen Liu, Gui-Hui Tu

Biochem Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin.
Shanshan Lin, Guihui Tu, Zelei Yu, Qingna Jiang, Lingyu Zhang

Bioorg Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
Quanyu Liu, Guihui Tu, Yan Hu, Qingna Jiang, Jingwen Liu

Eur J Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positive Feedback Regulation of Poly(ADP-ribose) Polymerase 1 and the DNA-PK Catalytic Subunit Affects the Sensitivity of Nasopharyngeal Carcinoma to Etoposide.
Lingyu Zhang, Yingting Zhuang, Guihui Tu, Ding Li, Yingjuan Fan

ACS Omega· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Chemotherapeutic Efficacy of PLGA-Encapsulated Epigallocatechin Gallate (EGCG) Against Human Lung Cancer.
Lingyu Zhang, Wenshu Chen, Guihui Tu, Xingyong Chen, Youguang Lu

Int J Nanomedicine· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis